Atlas Trials

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Clinical trial NCT06435429 · RECRUITING

Trial details

NCT number
NCT06435429
Sponsor
Jazz Pharmaceuticals
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Metastatic HER2-positive Breast Cancer
Start date
2024-08-13
Primary completion
2028-04-28
Enrollment
550

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.